Equities research analysts forecast that Horizon Therapeutics PLC (NASDAQ:HZNP) will post earnings per share (EPS) of $0.48 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Horizon Therapeutics’ earnings. The lowest EPS estimate is $0.37 and the highest is $0.51. Horizon Therapeutics posted earnings per share of $0.65 in the same quarter last year, which indicates a negative year-over-year growth rate of 26.2%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Horizon Therapeutics will report full-year earnings of $1.80 per share for the current fiscal year, with EPS estimates ranging from $1.61 to $1.89. For the next financial year, analysts forecast that the business will post earnings of $2.01 per share, with EPS estimates ranging from $1.71 to $2.22. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Horizon Therapeutics.
Horizon Therapeutics (NASDAQ:HZNP) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.14. The business had revenue of $320.60 million during the quarter, compared to analyst estimates of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.48 EPS.
A number of research analysts have weighed in on the company. TheStreet lowered Horizon Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, June 10th. BidaskClub raised Horizon Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Citigroup raised Horizon Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $21.00 to $32.00 in a report on Wednesday, May 1st. Mizuho set a $27.00 target price on Horizon Therapeutics and gave the company a “hold” rating in a report on Wednesday, May 8th. Finally, BMO Capital Markets raised Horizon Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $29.00 to $36.00 in a report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $32.73.
In other Horizon Therapeutics news, insider Jeff Kent sold 3,620 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total value of $89,196.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy P. Walbert sold 56,836 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $28.00, for a total value of $1,591,408.00. The disclosure for this sale can be found here. Insiders sold a total of 235,039 shares of company stock valued at $6,454,251 in the last 90 days. 4.10% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in HZNP. FMR LLC lifted its position in Horizon Therapeutics by 165.1% in the first quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock valued at $137,575,000 after purchasing an additional 3,242,071 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Horizon Therapeutics by 1,910.0% in the second quarter. Nuveen Asset Management LLC now owns 1,672,839 shares of the biopharmaceutical company’s stock valued at $40,249,000 after purchasing an additional 1,589,614 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Horizon Therapeutics in the first quarter valued at approximately $27,663,000. Price T Rowe Associates Inc. MD lifted its position in Horizon Therapeutics by 1,774.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,101,748 shares of the biopharmaceutical company’s stock valued at $26,508,000 after purchasing an additional 1,042,969 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Horizon Therapeutics by 11.4% in the second quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock valued at $210,628,000 after purchasing an additional 896,500 shares during the last quarter. Hedge funds and other institutional investors own 86.46% of the company’s stock.
HZNP stock traded down $0.49 during mid-day trading on Friday, reaching $27.19. 677,913 shares of the company traded hands, compared to its average volume of 1,867,306. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12. The company has a market capitalization of $5.07 billion, a P/E ratio of 14.86, a P/E/G ratio of 1.62 and a beta of 0.88. Horizon Therapeutics has a 52-week low of $16.56 and a 52-week high of $29.44. The company has a fifty day moving average price of $25.07 and a 200-day moving average price of $25.19.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Recommended Story: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.